Grant & Eisenhofer’s Beth Graham One of Three Selected to Lead Zofran (ondansetron) MDL

After more than 100 cases over GlaxoSmithKline’s “off label” marketing of its anti-nausea drug Zofran (ondansetron) were centralized under one umbrella in a multidistrict litigation (“MDL”), Massachusetts district Judge Dennis Saylor presiding over the litigation has selected three pharmaceutical mass tort attorneys to lead the litigation. Grant & Eisenhofer Director Beth Graham was appointed as co-lead counsel in the litigation surrounding the drug giant’s alleged negligent marketing of Zofran (ondansetron) for unapproved uses, for which plaintiffs claim caused congenital heart defects and cleft palate in infants who were exposed to the drug in utero.

Grant & Eisenhofer has been at the forefront of the litigation since its inception, filing the first case, and over 20 others, against GlaxoSmithKline on behalf of women and families affected by Zofran (ondansetron). Call us today at 877-978-0169 if you or a loved one took Zofran (ondansetron) during your first trimester and your child was born with a congenital heart defect or cleft palate. You may be entitled to compensation for pain and suffering, medical costs, loss of income, emotional distress and other damages.

Real Time Analytics